Cromwell Holdings’s Moderna MRNA Stock Holding History

Cromwell Holdings’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$88.2K	Buy	1,259 +51	+4%	+$2.64K	0.04%	379
2026 Q1	$61.4K	Buy	1,208 +8	+0.7%	+$373	0.03%	437
2025 Q4	$35.4K	Buy	1,200 +341	+40%	+$9.26K	0.02%	516
2025 Q3	$22.2K	Sell	859 -319	-27%	-$8.9K	0.01%	572
2025 Q2	$32.5K	Buy	+1,178	New	+$31K	0.02%	524
2025 Q1	–	Sell	-316	Closed	-$13.1K	–	825
2024 Q4	$13.1K	Buy	+316	New	+$15.1K	0.01%	593
2024 Q3	–	Sell	-1,021	Closed	-$121K	–	625
2024 Q2	$121K	Buy	+1,021	New	+$129K	0.07%	237

Other funds holding MRNA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

REX Advisers Fairfield, Connecticut $37.3M AUM

BDF Gestion Paris, France $747M AUM 47.35% 1-Year Est. Return

Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return

Mirabaud & Cie Geneva, Switzerland $249M AUM 43.75% 1-Year Est. Return

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return